
# **Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults**

Céline Fombellida-Lopez<sup>1</sup>, Alexander O. Pasternak<sup>2</sup>, Aurelija Cicilionyté<sup>2</sup>, Nathalie Maes<sup>1,4</sup>, Etienne Cavalier<sup>1,4</sup>, Lee Winchester<sup>3</sup>, Courtney V. Fletcher<sup>3</sup>, Fabrice Susin<sup>4</sup>, Dolores Vaira<sup>4</sup>, Marie-Pierre Hayette<sup>1,4</sup>, Catherine Reenaers<sup>1,4</sup>, Michel Moutschen<sup>1,4</sup>, Gilles Darcis<sup>1,4</sup>

<sup>1</sup>University of Liège, Liège, Belgium, <sup>2</sup>University of Amsterdam, Netherlands, <sup>3</sup>University of Nebraska Medical Center, Omaha, Nebraska, US, <sup>4</sup>University Hospital of Liège, Liège, Belgium

- leads to low-level residual viremia is still debated.
- regimen by doubling dolutegravir (DTG) dosage.
- activation, and inflammation.



Author Contact Information: cfombellidalopez@uliege.be We would like to acknowledge the study participants and funding resources that have made this work possible.

00429



🚺 🖌 LIÈGE universi



